ILA was an independent risk factor for shorter survival in stage I non-small-cell lung cancer (NSCLC) in the Boston lung cancer study, where more pronounced ILA increased the risk for death (HR = 2.88) after adjusting for age, sex, smoking, and treatment [58]. This evidence concerns the gene TNFRSF9 and non-small cell lung carcinoma.